Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ALPHA_SYN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| C3 | activates | protein | 0.56 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Long-term perampanel treatment in A53T BAC-SNCA mice with PFF injectio | validation | Lewy body disease | 0.950 | 0.00 | A53T BAC-SNCA transgenic mice | proposed | N/A |
| Longitudinal TLR2 reporter gene study in α-synuclein mice | validation | Parkinson's disease | 0.900 | 0.00 | Thy1.2-α-synuclein transgenic | proposed | N/A |
| PFF uptake in primary hippocampal neurons with inhibitors | exploratory | Lewy body disease | 0.900 | 0.00 | mouse primary hippocampal neur | proposed | N/A |
| Dexamethasone treatment study in α-synuclein mice | validation | Parkinson's disease | 0.850 | 0.00 | Thy1.2-α-synuclein transgenic | proposed | N/A |
| PFF clearance kinetics in Snca knockout mice | validation | Lewy body disease | 0.800 | 0.00 | Snca knockout mice | proposed | N/A |
| TLR expression in α-synuclein overexpressing mice | validation | Parkinson's disease | 0.800 | 0.00 | mice overexpressing human α-sy | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391] | Lin Aung T, Aung YW, Shi X | Biomed Phys Eng Express | 2026 | 1 |
| A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647] | Tran HD, Shin MK, Yeo XY, Jung S, Junaid | Brain | 2026 | 0 |
| Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593] | Boyd RJ, Kho AR, McClymont SA, Loftus SK | Brain | 2026 | 0 |
| Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763] | Ueda J, Uemura N, Chang J, Hirato T, Ish | Mov Disord | 2026 | 0 |
| Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889] | Fraser KB, Mirelman A, Mabrouk OS, Omer | J Parkinsons Dis | 2026 | 0 |
| Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116] | Wang Y, Lipton SA | J Neurochem | 2026 | 0 |
| SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927] | Statoulla E, Zafeiri M, Chalkiadaki K, V | NPJ Parkinsons Dis | 2026 | 0 |
| Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496] | Panda SP, Saraswat N, Singh V | Neuroscience | 2026 | 0 |
| Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943] | Kabuta C, Hakuno F, Kataoka N, Takahashi | Neurochem Int | 2026 | 0 |
| An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745] | Asmi S, Krishnan A, Alexander SM, Mohame | Ageing Res Rev | 2026 | 0 |
| N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663] | Song P, Chen C, Franchini R, Duong B, Wa | J Clin Invest | 2026 | 0 |
| Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621] | ["Singh R", "Maity P", "Jaiswal C"] | Neurochemistry international | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning ALPHA_SYN in their description or question text
Score: 0.582 · neurodegeneration · 2026-04-25
Membrane-derived cofactors in extracellular vesicles maintain polymorph fidelity and templating competence.
Score: 0.571 · neurodegeneration · 2026-04-04
## Mechanistic Overview Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization starts from the claim that mo
Score: 0.560 · neurodegeneration · 2026-04-24
The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition,
Score: 0.550 · neurodegeneration · 2026-04-24
A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in sus
Score: 0.489 · neurodegeneration · 2026-04-25
Electrostatic bridging by glycans and low-abundance proteins preserves disease-relevant fibril architecture.
Score: 0.440 · neurodegeneration · 2026-04-24
Propionate is the most plausible exploratory monotherapy candidate only because it may have somewhat more realistic syst